Trial site
Utah Cancer Specialists
- 32running trials
- 18closed trials
The trials here
What the 50 trials at this site are about, from their registry records.
- Conditions
- Lung cancer15 trials
- Colorectal cancer10 trials
- Pancreatic cancer10 trials
- Gastric and oesophageal cancer5 trials
- Head and neck cancer5 trials
- Melanoma5 trials
- Metastatic breast cancer5 trials
- Ovarian cancer5 trials
- Prostate cancer5 trials
- Endometrial cancer4 trials
- Kidney cancer4 trials
- Multiple myeloma4 trials
- and 12 more
- Phase
- Phase 326 trials
- Phase 214 trials
- Phase 1/25 trials
- Phase 2/33 trials
- Status
- Active, not recruiting21 trials
- Completed13 trials
- Recruiting11 trials
- Terminated5 trials
- Lead sponsor
- Janssen Research & Development, LLC8 trials
- Eli Lilly and Company5 trials
- Astellas Pharma Global Development, Inc.3 trials
- Incyte Corporation3 trials
- Novartis Pharmaceuticals3 trials
- and 24 more
Running trials
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Active, not recruiting
Active, not recruiting
Recruiting
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Active, not recruiting
Active, not recruiting
Active, not recruiting
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Active, not recruiting
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Active, not recruiting
Active, not recruiting
Recruiting
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Active, not recruiting
Active, not recruiting
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Active, not recruiting
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Colorectal cancer3 recruiting
- Gastric and oesophageal cancer2 recruiting
- Head and neck cancer2 recruiting
- Lung cancer2 recruiting
- Multiple myeloma2 recruiting
- Ovarian cancer2 recruiting
- Pancreatic cancer2 recruiting
- Bladder cancer1 recruiting
- Endometrial cancer1 recruiting
- Immune thrombocytopenia (ITP)1 recruiting
- Kidney cancer1 recruiting
- Melanoma1 recruiting
- Metastatic breast cancer1 recruiting
- Prostate cancer1 recruiting
Closed trials
Completed
Completed
Terminated
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
Completed
Completed
Terminated
Terminated
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Completed
Completed
Completed
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
Completed
Completed
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Completed
Completed
Completed
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Terminated
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Terminated
Completed
Site data: ClinicalTrials.govUpdated 18 Nov 2026